In this month’s newsletter, we highlight and build upon our knowledge working with the Tau[P301S] mouse model (originally described by Allen et al., 2002), and its applicability in preclinical research.

Female and male Tau[P301S] mouse model phenotyping to inform translational preclinical study designs 

The Homozygous Tau[P301S] (Thy1_TauP301S) mouse is one of the most widely used preclinical models for evaluating efficacy of therapeutics against tauopathies (Langness et al., 2025). Although limited evidence suggests that male Tau[P301S] mice exhibit a similar onset of tau pathology as females (Woerman et al., 2017), their behavioral and phenotypic profiles remain undercharacterized.  

In a recent internal validation study that was presented earlier this year at AD/PD 2026, InnoSer performed a comprehensive longitudinal characterization of both male and female Tau[P301S] mice, integrating behavioral, cognitive, home-cage, and biomarker endpoints to integrate novel insights to strengthen translational study design opportunities for future preclinical programs.

Female Tau[P301S] mice show early spontaneous hyperactivity in automated home-cages (PhenoTyperTM) 

FIGURE 1. Female Tau[P301S] mice display increased spontaneous activity compared with males. (A) Spontaneous behavior was assessed in automated PhenoTyper home-cages, enabling analysis of over 115 behavioral parameters. (B) Female mice exhibit pronounced hyperactivity at younger ages, gradually diminishing with age. (C) Both male and female mice frequently climb on their shelter, with this behavior decreasing over time, potentially reflecting progression of motor symptoms.

Male and female Tau[P301S] mice develop comparable early motor coordination deficits

FIGURE 2. Male and female Tau[P301S] mice develop comparable motor coordination deficits. Motor coordination assessed using the Balance Beam Test shows increased slips with no significant differences between males and females. 

FIGURE 3. Female Tau[P301S] mice display spatial memory deficits in the Morris Water Maze. (A) During training, both male and female mice showed increased latency to locate the hidden platform compared with WT controls. (B–C) In the probe trial, female Tau[P301S] mice showed reduced spatial memory performance compared with WT animals, evidenced by (B) fewer crossings of the former platform location (C) and reduced time spent in the target platform zone. (D) Swimming velocity during the probe trial was similar across groups, indicating that the observed differences are not explained by motor or swimming impairments. 

Female Tau[P301S] mice exhibit selective discrimination learning deficits during the CognitionWallTM task

FIGURE 4. Female Tau[P301S] mice exhibit selective discrimination learning deficits, assessed using the (A) CognitionWall™ (CW), whereby mice learn to preferentially pass through the rewarded entrance of a three-choice wall to obtain a food reward. (B) In the CW task, female Tau[P301S] mice made more entries to reach the learning criterion compared with male Tau[P301S] mice and WT controls, demonstrating a selective deficit in discrimination learning.

In this newsletter, we have presented data, providing new insights into both shared and sex-specific phenotypes, supporting more informed and translationally relevant study design for tau-targeted therapeutic programs.  

Interested in performing efficacy studies in the Tau[P301S] mouse model? InnoSer has generated extensive additional validation data in the Tau[P301S] model, including behavioral assessments, biomarkers (total and phosphorylated tau in CSF/plasma, plasma neurofilament light chain), and histopathological endpoints such as tau phosphorylation, astrocytosis, microgliosis, and neuronal loss.  

Le développement de médicaments peut être un processus long et itératif. InnoSer peut être votre partenaire dédié dans ce domaine, en vous offrant des délais d’exécution rapides grâce à des expériences menées en chaîne afin de vous aider à optimiser vos composés phares. Vous souhaitez en savoir plus sur les compétences d’InnoSer dans le domaine du développement de médicaments ?   

Prêt à faire passer votre recherche préclinique au niveau supérieur ?Travaillons ensemble pour que vos nouvelles thérapies donnent des résultats cliniques optimaux.